{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T10:38:25Z","timestamp":1766486305860,"version":"3.40.5"},"reference-count":14,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.vaccine.2024.04.059","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T20:33:31Z","timestamp":1714854811000},"page":"3536-3546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study"],"prefix":"10.1016","volume":"42","author":[{"given":"Vicky","family":"C\u00e1rdenas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Le Gars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Truyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6941-3100","authenticated-orcid":false,"given":"Javier","family":"Ruiz-Gui\u00f1az\u00fa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Struyf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5171-4393","authenticated-orcid":false,"given":"Alicia","family":"Colfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bonten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Borobia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil C.","family":"Reisinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid M.C.","family":"Kamerling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macaya","family":"Douoguih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerald","family":"Sadoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.04.059_b0005","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.04.059_b0010","unstructured":"Our World in Data. Coronavirus (COVID-19) Vaccinations. Accessed April 12, 2024. Available from https:\/\/ourworldindata.org\/covid-vaccinations."},{"key":"10.1016\/j.vaccine.2024.04.059_b0015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41541-020-00243-x","article-title":"Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses","volume":"5","author":"Bos","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2024.04.059_b0020","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S1473-3099(22)00506-0","article-title":"Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Hardt","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.04.059_b0025","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.04.059_b0030","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa2117608","article-title":"Final analysis of efficacy and safety of single-dose Ad26.COV2.S","volume":"386","author":"Sadoff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.04.059_b0035","unstructured":"European Medicines Agency. Jcovden (previously COVID-19 Vaccine Janssen) Summary of Product Characterstics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jcovden-previously-covid-19-vaccine-janssen-epar-product-information_en.pdf [accessed 16 October 2023]."},{"key":"10.1016\/j.vaccine.2024.04.059_b0040","unstructured":"World Health Organization. The Janssen Ad26.COV2.S COVID-19 vaccine: What you need to know. 6 June 2022 https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-j-j-covid-19-vaccine-what-you-need-to-know [accessed 16 October 2023]."},{"key":"10.1016\/j.vaccine.2024.04.059_b0045","article-title":"Accelerated and intensified manufacturing of an adenovirus-vectored vaccine to enable rapid outbreak response","author":"Joe","year":"2023","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2024.04.059_b0050","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMc2108829","article-title":"Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination","volume":"385","author":"Barouch","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.04.059_b0055","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M20-5306","article-title":"A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine","volume":"174","author":"Salisch","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2024.04.059_b0060","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a Phase 1\u20132a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.04.059_b0065","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12979-019-0164-9","article-title":"Immunosenescence and human vaccine immune responses","volume":"16","author":"Crooke","year":"2019","journal-title":"Immun Ageing"},{"key":"10.1016\/j.vaccine.2024.04.059_b0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/imr.13089","article-title":"Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines","volume":"310","author":"Sette","year":"2022","journal-title":"Immunol Rev"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24004961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24004961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T19:08:20Z","timestamp":1716577700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24004961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":14,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0264410X24004961"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.059","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}